Marker Therapeutics, Inc.

Monthly Archives: April 2016

TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

…JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd – 5th, 2016 at Caesars Palace in Las Vegas, Nevada.

Read More

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

…JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ –

Study to commence Q2 2016 at Sloan Kettering Institute
Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients
TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FR�), in combination with Astra Zeneca (NYSE: AZN) durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer.

Read More

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

…Doses for use at Mayo Clinic and other clinical sites

Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, its multi-epitope folate receptor peptide vaccine for breast and ovarian cancer.

Read More